IN2014CN02959A - - Google Patents
Info
- Publication number
- IN2014CN02959A IN2014CN02959A IN2959CHN2014A IN2014CN02959A IN 2014CN02959 A IN2014CN02959 A IN 2014CN02959A IN 2959CHN2014 A IN2959CHN2014 A IN 2959CHN2014A IN 2014CN02959 A IN2014CN02959 A IN 2014CN02959A
- Authority
- IN
- India
- Prior art keywords
- compounds
- formula
- abvdisclosed
- het
- salts
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161552885P | 2011-10-28 | 2011-10-28 | |
| PCT/US2012/062207 WO2013063459A1 (en) | 2011-10-28 | 2012-10-26 | Benzoxazolinone compounds with selective activity in voltage-gated sodium channels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN02959A true IN2014CN02959A (de) | 2015-07-03 |
Family
ID=48168585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2959CHN2014 IN2014CN02959A (de) | 2011-10-28 | 2012-10-26 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9273040B2 (de) |
| EP (1) | EP2770995B1 (de) |
| JP (1) | JP2014532660A (de) |
| KR (1) | KR20140095067A (de) |
| CN (1) | CN103889419A (de) |
| AU (1) | AU2012328561A1 (de) |
| BR (1) | BR112014010197A2 (de) |
| CA (1) | CA2852796A1 (de) |
| IN (1) | IN2014CN02959A (de) |
| MX (1) | MX2014005068A (de) |
| RU (1) | RU2014121489A (de) |
| WO (1) | WO2013063459A1 (de) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2773641B1 (de) | 2011-10-31 | 2017-09-27 | Xenon Pharmaceuticals Inc. | Biarylethersulfonamide und ihre verwendung als arzneimittel |
| CA2853439A1 (en) | 2011-10-31 | 2013-05-10 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| MX2014014234A (es) | 2012-05-22 | 2015-05-07 | Genentech Inc | Benzamidas n-sustituidas y su uso en el tratamiento del dolor. |
| KR101663436B1 (ko) | 2012-07-06 | 2016-10-06 | 제넨테크, 인크. | N-치환된 벤즈아미드 및 이의 사용 방법 |
| KR20150131233A (ko) | 2013-03-14 | 2015-11-24 | 제넨테크, 인크. | 치환된 트리아졸로피리딘 및 이의 사용 방법 |
| US9493429B2 (en) | 2013-03-15 | 2016-11-15 | Genentech, Inc. | Substituted benzoxazoles and methods of use thereof |
| CR20160296A (es) | 2013-11-27 | 2016-09-20 | Genentech Inc | Benzamidas sustituidas y métodos para usarlas |
| TW201623264A (zh) | 2014-03-29 | 2016-07-01 | 魯賓有限公司 | 作為電位閘控鈉通道調節劑之磺胺化合物 |
| US10005724B2 (en) | 2014-07-07 | 2018-06-26 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| MX2017011042A (es) * | 2015-03-02 | 2018-03-02 | Amgen Inc | Compuestos biciclicos de sulfonamida cetona. |
| KR20180008761A (ko) | 2015-05-22 | 2018-01-24 | 제넨테크, 인크. | 치환된 벤즈아미드 및 이의 이용 방법 |
| JP2018526371A (ja) | 2015-08-27 | 2018-09-13 | ジェネンテック， インコーポレイテッド | 治療化合物及びその使用方法 |
| RU2018115718A (ru) | 2015-09-28 | 2019-10-28 | Дженентек, Инк. | Терапевтические соединения и способы их применения |
| EP3380466A1 (de) | 2015-11-25 | 2018-10-03 | Genentech, Inc. | Substituierte benzamide als natriumkanalblocker |
| KR20180095598A (ko) | 2015-12-18 | 2018-08-27 | 머크 샤프 앤드 돔 코포레이션 | 전압-게이팅 나트륨 채널에서 선택적 활성을 갖는 히드록시알킬아민- 및 히드록시시클로알킬아민-치환된 디아민-아릴술폰아미드 화합물 |
| EP3436432B1 (de) | 2016-03-30 | 2021-01-27 | Genentech, Inc. | Substituierte benzamide und verfahren zur verwendung davon |
| KR102366077B1 (ko) | 2016-05-20 | 2022-02-21 | 제논 파마슈티칼스 인크. | 벤젠술폰아미드 화합물 및 치료제로서의 그의 용도 |
| MX2019004232A (es) | 2016-10-17 | 2019-08-01 | Genentech Inc | Compuestos terapéuticos y métodos para utilizarlos. |
| CN110325531B (zh) | 2016-12-09 | 2022-05-27 | 泽农医药公司 | 苯磺酰胺及其作为治疗剂的用途 |
| EP3601273B1 (de) | 2017-03-24 | 2021-12-01 | Genentech, Inc. | 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamid-derivate als natriumkanalinhibitoren |
| TW201908310A (zh) * | 2017-05-11 | 2019-03-01 | 英商葛蘭素史克智慧財產發展有限公司 | 化合物 |
| EP3759098A1 (de) | 2018-02-26 | 2021-01-06 | Genentech, Inc. | Pyridinsulfonamidverbindungen und deren verwendung gegen schmerz und verwandte störungen |
| JP2021519788A (ja) | 2018-03-30 | 2021-08-12 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ナトリウムチャネル阻害剤としての縮合環ヒドロピリド化合物 |
| US11512072B2 (en) | 2018-04-19 | 2022-11-29 | University Of Virginia Patent Foundation | Compositions and methods for preparing and using azetidines |
| US10745392B2 (en) | 2018-06-13 | 2020-08-18 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| JP7383012B2 (ja) | 2018-08-31 | 2023-11-17 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ヘテロアリール置換スルホンアミド化合物、およびナトリウムチャネル阻害剤としてのその使用 |
| MX2021001380A (es) | 2018-08-31 | 2021-05-27 | Xenon Pharmaceuticals Inc | Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapeuticos. |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09124620A (ja) * | 1995-10-11 | 1997-05-13 | Bristol Myers Squibb Co | 置換ビフェニルスルホンアミドエンドセリン拮抗剤 |
| WO2000034248A1 (en) * | 1998-12-04 | 2000-06-15 | Neurosearch A/S | New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents |
| EP1598340B1 (de) | 2001-04-18 | 2009-03-04 | Euro-Celtique S.A. | 1-(4-piperidinyl)-1,3-dihydro-2h-benzoxazole-2-one derivate und verwandte verbindungen als nociceptin analoge und orl1 liganden zur behandlung von schmerz |
| EP1467986A1 (de) | 2002-01-17 | 2004-10-20 | Eli Lilly And Company | Azacyclische verbindungen als modulatoren von acetylcholinrezeptoren |
| US7786137B2 (en) * | 2005-05-10 | 2010-08-31 | Vertex Pharmaceuticals Incorporated | Bicyclic derivatives as modulators of ion channels |
| ZA200800191B (en) * | 2005-06-09 | 2009-04-29 | Vertex Pharmaceuicals Inc | Indane derivatives as modulators of ion channels |
| CN101365686A (zh) | 2005-12-21 | 2009-02-11 | 沃泰克斯药物股份有限公司 | 作为离子通道调节剂的杂环衍生物 |
| JP5460589B2 (ja) * | 2007-07-13 | 2014-04-02 | アイカジェン， インコーポレイテッド | ナトリウムチャネル阻害物質 |
| CN102159077A (zh) | 2008-08-21 | 2011-08-17 | 吉瑞工厂 | 用于治疗神经性疼痛的方法 |
| GEP20135992B (en) | 2009-01-12 | 2013-12-25 | Icagen Inc | Sulfonamide derivatives |
| PL2427441T3 (pl) * | 2009-05-04 | 2017-06-30 | Agios Pharmaceuticals, Inc. | Aktywatory PKM2 do stosowania w leczeniu raka |
-
2012
- 2012-10-26 AU AU2012328561A patent/AU2012328561A1/en not_active Abandoned
- 2012-10-26 EP EP12843015.4A patent/EP2770995B1/de active Active
- 2012-10-26 JP JP2014539066A patent/JP2014532660A/ja active Pending
- 2012-10-26 US US14/353,488 patent/US9273040B2/en active Active
- 2012-10-26 IN IN2959CHN2014 patent/IN2014CN02959A/en unknown
- 2012-10-26 CN CN201280052937.2A patent/CN103889419A/zh active Pending
- 2012-10-26 KR KR1020147013911A patent/KR20140095067A/ko not_active Application Discontinuation
- 2012-10-26 WO PCT/US2012/062207 patent/WO2013063459A1/en active Application Filing
- 2012-10-26 CA CA2852796A patent/CA2852796A1/en not_active Abandoned
- 2012-10-26 BR BR112014010197A patent/BR112014010197A2/pt not_active IP Right Cessation
- 2012-10-26 RU RU2014121489/04A patent/RU2014121489A/ru not_active Application Discontinuation
- 2012-10-26 MX MX2014005068A patent/MX2014005068A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US9273040B2 (en) | 2016-03-01 |
| EP2770995A1 (de) | 2014-09-03 |
| EP2770995A4 (de) | 2015-06-03 |
| US20140303143A1 (en) | 2014-10-09 |
| BR112014010197A2 (pt) | 2017-04-18 |
| KR20140095067A (ko) | 2014-07-31 |
| RU2014121489A (ru) | 2015-12-10 |
| AU2012328561A1 (en) | 2014-04-17 |
| MX2014005068A (es) | 2014-07-30 |
| EP2770995B1 (de) | 2019-01-02 |
| AU2012328561A8 (en) | 2014-05-01 |
| CN103889419A (zh) | 2014-06-25 |
| JP2014532660A (ja) | 2014-12-08 |
| WO2013063459A1 (en) | 2013-05-02 |
| CA2852796A1 (en) | 2013-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CN02959A (de) | ||
| PH12019501321B1 (en) | Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders | |
| PH12018501288A1 (en) | Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels | |
| SA515360229B1 (ar) | مثبطات عامل التمايز والنمو 8 | |
| SA515360469B1 (ar) | مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها | |
| PH12015501661A1 (en) | Pyridone amides as modulators of sodium channels | |
| BR112015009216A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de uma composição farmacêutica | |
| CL2015001599A1 (es) | Compuestos derivados de (piridin o pirimidin)-(piperidina o piperazina) sustituidos o sus sales, inhibidores de la colesterol 24-hidroxilasa (ch24h); medicamento; metodo de inhibicion de la ch24h; metodo para prevenir o tratar; y uso para la prevencion o tratamiento de epilepsia, alzheimer y parkinson, entre otras enfermedades. | |
| MX2015008957A (es) | Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1). | |
| HUE036040T2 (hu) | Adaptor-asszociált kináz 1 gátlása fájdalom kezelésére | |
| PH12015502365A1 (en) | Bace1 inhibitors | |
| MX2012001134A (es) | Composiciones y metodos para inhibicion de la via jak. | |
| PH12014502541A1 (en) | 5-amino [1,4] thiazines as bace 1 inhibitors | |
| WO2013040227A3 (en) | Therapeutic compounds | |
| NZ738672A (en) | Therapeutic compounds and compositions for treating social disorders and substance use disorders | |
| WO2014043252A3 (en) | Hydroxypyridinone-,hydroxypyrimidinone-and hydroxypyridazinone drivatives and their therapeutic application | |
| WO2014035846A3 (en) | Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use | |
| TN2015000275A1 (fr) | 4-hydroxy-2-methyl-5-(propan-2-ylidene)cyclohex-3-enecarbaldehyde for the prevention and treatment of a cognitive, neurodegenerative or neuronal disease | |
| IN2012DN06061A (de) | ||
| WO2013148638A3 (en) | Compositions and methods related to inhibitors of jak kinase | |
| TN2013000150A1 (en) | Co-crystals and salts of ccr3-inhibitors | |
| WO2013121334A3 (en) | Agents for treating neurodegenerative disorders | |
| WO2013175347A3 (en) | Compositions and methods for treatment of respiratory disorders |